drugset / Trial / NCT00921557

Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents

NCT00921557

RandomizedCrossoverDouble-blindTreatment

Summary

HIV-infected children, youth, and adults have lower bone mineral density (BMD) than would be expected for HIV-uninfected people of similar age, weight and race. As the majority of perinatally HIV-infected U.S. children are entering or in adolescence, the potential for HIV-related impaired BMD during the adolescent peak of bone mass acquisition is of particular concern. The primary purpose of this study was to compare changes from pre-treatment levels of BMD of the lumbar spine after 24 and 48 weeks of alendronate treatment with placebo in HIV-infected children and adolescents.

Timeline

Start
2009-11
Primary completion
2016-01
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 35 mg Oral
Subject Alendronic Acid Small molecule 70 mg Oral